Current Status
Not Enrolled
Get Started

Jointly provided by Partners for Advancing Clinical Education (PACE) and Ig National Society, Inc.

Release Date: November 1, 2023
Expiration Date: October 31, 2024

Target Audience
This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients in need of immunoglobulin therapy and specialty biologics.

Educational Objectives
Upon completion of this activity, participants should be able to:

  • Discuss the disease and treatment burdens of generalized myasthenia gravis
  • Explain the pathogenic mechanisms of disease in myasthenia gravis
  • Identify the role of FcRn inhibition in the treatment of myasthenia gravis
  • Describe the role of complement inhibition in myasthenia gravis

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Ig National Society, Inc. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.

Pharmacy Continuing Education
PACE designates this continuing education activity for 1.0 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008073-9999-24-022-H01-P)
Type of Activity: Knowledge

Faculty & Disclosures

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

James Howard, MD, FANN
Professor of Neurology, Medicine & Allied Health
Director, Myasthenia Gravis Clinical Trials and Translational Research Program
The University of North Carolina at Chapel Hill
Adjunct Professor of Clinical Sciences (Neurology)
North Carolina State University College of Veterinary Medicine
Faculty Conflicts of Interest
Conflicts of Interest: Honoraria: AcademicCME, Alexion Pharmaceuticals, Argenx, Biologix Pharma, Medscape CME, PeerView CME, Ra Pharmaceuticals, F. Hoffman-LaRoche Ltd, Immunovant, Merck EMB Serono, NMD Pharma, Novartis Pharma, Regeneron, Sanofi US, Toleranzia AB, Horizon Therapeutics, Zai Labs
Researcher: Alexion Pharmaceuticals, Argenx, Cartesian Therapeutics, The Centers for Disease Control and Prevention, Millenium Pharmaceuticals, National Institutes of Health, PCORI, Ra Pharmaceuticals
Individual publicly traded stocks and stock options: Johnson & Johnson, Pfizer, General Electric, GlaxoSmithKline, GE Healthcare, Viatris

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions for Credit
Participation in this self-study activity should be completed in 1 hour. To successfully complete activities and receive CE credit, learners must follow these steps:

  1. Review the objectives and disclosures
  2. Study the educational content
  3. Visit
  4. Complete the activity evaluation
  5. Upon completion of all evaluation questions your credit will be made available for download immediately.

Pharmacists: Upon successfully completing the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.
For additional information about the accreditation of this activity, please visit